Vertera

Vertero Therapeutics, formerly known as Axial Therapeutics, is a clinical-stage biotechnology company pioneering a novel approach to treating neurodegenerative diseases by targeting peripheral drivers in the gut. The company's lead candidate, VT-5006, is a first-in-class, gut-selective small molecule designed to inhibit the microbial amyloid CsgA, which is implicated in the aggregation of alpha-synuclein and the propagation of inflammation to the brain. By addressing these upstream triggers at their source in the gastrointestinal tract, Vertero aims to delay the onset and slow the progression of Parkinson's disease. The company is currently advancing its pipeline through early clinical development, supported by a seasoned leadership team and a focus on the interplay between the peripheral nervous system and brain health.